JP2022512994A5 - - Google Patents

Info

Publication number
JP2022512994A5
JP2022512994A5 JP2021525298A JP2021525298A JP2022512994A5 JP 2022512994 A5 JP2022512994 A5 JP 2022512994A5 JP 2021525298 A JP2021525298 A JP 2021525298A JP 2021525298 A JP2021525298 A JP 2021525298A JP 2022512994 A5 JP2022512994 A5 JP 2022512994A5
Authority
JP
Japan
Prior art keywords
retroviral vector
seq
vector according
acid sequence
bisistronic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021525298A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512994A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/061549 external-priority patent/WO2020102589A1/en
Publication of JP2022512994A publication Critical patent/JP2022512994A/ja
Publication of JP2022512994A5 publication Critical patent/JP2022512994A5/ja
Priority to JP2025001976A priority Critical patent/JP2025072367A/ja
Pending legal-status Critical Current

Links

JP2021525298A 2018-11-14 2019-11-14 Car-t細胞を生成する2遺伝子ベクターおよびその使用 Pending JP2022512994A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025001976A JP2025072367A (ja) 2018-11-14 2025-01-06 Car-t細胞を生成する2遺伝子ベクターおよびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862767069P 2018-11-14 2018-11-14
US62/767,069 2018-11-14
PCT/US2019/061549 WO2020102589A1 (en) 2018-11-14 2019-11-14 Two-gene vectors for generating car-t cells and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025001976A Division JP2025072367A (ja) 2018-11-14 2025-01-06 Car-t細胞を生成する2遺伝子ベクターおよびその使用

Publications (2)

Publication Number Publication Date
JP2022512994A JP2022512994A (ja) 2022-02-07
JP2022512994A5 true JP2022512994A5 (cg-RX-API-DMAC10.html) 2022-11-22

Family

ID=70732194

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021525298A Pending JP2022512994A (ja) 2018-11-14 2019-11-14 Car-t細胞を生成する2遺伝子ベクターおよびその使用
JP2025001976A Pending JP2025072367A (ja) 2018-11-14 2025-01-06 Car-t細胞を生成する2遺伝子ベクターおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025001976A Pending JP2025072367A (ja) 2018-11-14 2025-01-06 Car-t細胞を生成する2遺伝子ベクターおよびその使用

Country Status (10)

Country Link
US (1) US20210395779A1 (cg-RX-API-DMAC10.html)
EP (1) EP3864052A4 (cg-RX-API-DMAC10.html)
JP (2) JP2022512994A (cg-RX-API-DMAC10.html)
KR (1) KR20210091250A (cg-RX-API-DMAC10.html)
CN (2) CN120519520A (cg-RX-API-DMAC10.html)
AU (1) AU2019378039A1 (cg-RX-API-DMAC10.html)
CA (1) CA3119296A1 (cg-RX-API-DMAC10.html)
MA (1) MA53877A (cg-RX-API-DMAC10.html)
SG (1) SG11202104334SA (cg-RX-API-DMAC10.html)
WO (1) WO2020102589A1 (cg-RX-API-DMAC10.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20220890T1 (hr) 2015-02-06 2022-10-14 National University Of Singapore Postupci za povećanje učinkovitosti terapijskih imunosnih stanica
CN118581046A (zh) 2016-11-22 2024-09-03 新加坡国立大学 用于t细胞恶性肿瘤免疫疗法的cd7表达阻滞剂和嵌合抗原受体
GB201719646D0 (en) 2017-11-27 2018-01-10 Bivictrix Therapeutics Ltd Therapy
CN112300282A (zh) * 2020-11-03 2021-02-02 南京北恒生物科技有限公司 靶向cd7的人源化抗体及其用途
CN114525259B (zh) * 2020-11-03 2025-02-14 南京北恒生物科技有限公司 靶向cd7的嵌合抗原受体及其用途
CN114525306B (zh) * 2020-11-23 2025-01-28 博生吉医药科技(苏州)有限公司 一种cd7-car-t细胞的制备方法及应用
GB202020572D0 (en) * 2020-12-23 2021-02-03 Bivictrix Therapeutics Ltd Novel methods of therapy
GB202020573D0 (en) * 2020-12-23 2021-02-03 Bivictrix Therapeutics Ltd Novel methods of therapy
CN115786271B (zh) * 2021-01-12 2025-07-22 上海雅科生物科技有限公司 靶向cd7的工程化免疫细胞、嵌合抗原受体、cd7阻断分子及应用
US20240082306A1 (en) * 2021-02-03 2024-03-14 Bioheng Therapeutics Limited Novel chimeric antigen receptor and use thereof
EP4501953A4 (en) * 2022-03-29 2026-06-24 Inst Of Hematology And Blood Diseases Hospital Chinese Academy Of Medical Sciences Antibodies that bind specifically to CD7 and their use in the preparation of a chimeric antigen receptor
CN120025438A (zh) * 2023-11-21 2025-05-23 合源生物科技(天津)有限公司 一种靶向cd7的人源化抗体、嵌合抗原受体及其应用
CN118221810A (zh) * 2024-03-05 2024-06-21 武汉生物制品研究所有限责任公司 一种能够结合ev-a71的单克隆抗体及其应用
CN120865430A (zh) * 2024-04-30 2025-10-31 合源生物科技(天津)有限公司 一种增强型嵌合抗原受体及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
SG11201505896YA (en) * 2013-02-20 2015-09-29 Novartis Ag Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
IL298125A (en) * 2013-02-26 2023-01-01 Memorial Sloan Kettering Cancer Center Preparations and methods for immunotherapy
WO2016049024A2 (en) * 2014-09-24 2016-03-31 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling competition of multiple cancer mutations in vivo
HRP20220890T1 (hr) 2015-02-06 2022-10-14 National University Of Singapore Postupci za povećanje učinkovitosti terapijskih imunosnih stanica
SG11201807489PA (en) * 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
CN118581046A (zh) 2016-11-22 2024-09-03 新加坡国立大学 用于t细胞恶性肿瘤免疫疗法的cd7表达阻滞剂和嵌合抗原受体
CA3071282A1 (en) * 2017-08-10 2019-02-14 National University Of Singapore T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
JP7584299B2 (ja) * 2018-05-23 2024-11-15 ナショナル ユニバーシティ オブ シンガポール T細胞悪性腫瘍の免疫療法のためのcd2表面発現の遮断およびキメラ抗原受容体の発現
WO2019226946A1 (en) * 2018-05-23 2019-11-28 National University Of Singapore Chimeric antigen receptors and gene editing of cd2 for immunotherapy of t-cell malignancies

Similar Documents

Publication Publication Date Title
JP2022502056A5 (cg-RX-API-DMAC10.html)
JP2022523961A5 (cg-RX-API-DMAC10.html)
ES2199941T3 (es) Anticuerpos monoclonales contra el receptor de la interferona, con actividad neutralizadora contra el interferon de tipo j.
JP2021533779A5 (cg-RX-API-DMAC10.html)
JP2023504914A5 (cg-RX-API-DMAC10.html)
JP2022527635A5 (cg-RX-API-DMAC10.html)
JP2022502077A5 (cg-RX-API-DMAC10.html)
JP2024507929A5 (cg-RX-API-DMAC10.html)
JP2022542670A5 (cg-RX-API-DMAC10.html)
JP2011501951A5 (cg-RX-API-DMAC10.html)
JP2020505919A5 (cg-RX-API-DMAC10.html)
JP2024508683A5 (cg-RX-API-DMAC10.html)
JP2018531040A5 (cg-RX-API-DMAC10.html)
JP2023040169A5 (cg-RX-API-DMAC10.html)
JP2021531834A5 (cg-RX-API-DMAC10.html)
JP2023553697A5 (cg-RX-API-DMAC10.html)
JP2023528207A5 (cg-RX-API-DMAC10.html)
JP2026004299A5 (cg-RX-API-DMAC10.html)
JP2022505877A5 (cg-RX-API-DMAC10.html)
JP2023553694A5 (cg-RX-API-DMAC10.html)
JP2023500248A5 (cg-RX-API-DMAC10.html)
JP2024520427A5 (cg-RX-API-DMAC10.html)
JPWO2020059847A5 (cg-RX-API-DMAC10.html)
JP2024503091A5 (cg-RX-API-DMAC10.html)
JP2019514343A5 (cg-RX-API-DMAC10.html)